trending Market Intelligence /marketintelligence/en/news-insights/trending/lEAaoEqLi6aWv8firhQwcA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US drug pricing watchdog will probe BioMarin's hemophilia gene therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US drug pricing watchdog will probe BioMarin's hemophilia gene therapy

U.S. pricing watchdog the Institute for Clinical and Economic Review said that it will investigate BioMarin Pharmaceutical Inc.'s hemophilia A gene therapy valoctocogene roxaparvovec for cost-effectiveness.

ICER said that likely comparators for the cost assessment will be currently approved treatments for hemophilia A like factor VIII replacement therapy and Hemlibra, a drug from Roche Holding AG's Genentech. BioMarin's gene therapy is not yet approved, but the U.S. Food and Drug Administration is expected to make a decision by the middle of the year.

People with hemophilia A are missing or have low levels of a protein called factor VIII, and valoctocogene roxaparvovec introduces a gene in a single infusion that would enable the production of the protein.

BioMarin submitted its biologics license application to the FDA in December 2019, and the European Medicines Agency accepted the application in November the same year. Both regulators have designated it an orphan therapy with the U.S. additionally calling it a breakthrough.

ICER proposed changes to its cost effectiveness framework for gene therapies that could potentially be one-time "cures" for diseases rather than drugs that treat chronic conditions. Gene therapies like Novartis AG's Zolgensma or Spark Therapeutics Inc.'s Luxturna prompted pricing concern with initial pricetags of more than $1 million but a high potential for benefit for patients with rare diseases.

SNL Image